DK1425404T3 - Vaccinia-MVA-E3L-mutanter og anvendelse deraf - Google Patents
Vaccinia-MVA-E3L-mutanter og anvendelse derafInfo
- Publication number
- DK1425404T3 DK1425404T3 DK02772289T DK02772289T DK1425404T3 DK 1425404 T3 DK1425404 T3 DK 1425404T3 DK 02772289 T DK02772289 T DK 02772289T DK 02772289 T DK02772289 T DK 02772289T DK 1425404 T3 DK1425404 T3 DK 1425404T3
- Authority
- DK
- Denmark
- Prior art keywords
- mva
- viruses
- mutant
- present
- mutants
- Prior art date
Links
- 206010046865 Vaccinia virus infection Diseases 0.000 title 1
- 208000007089 vaccinia Diseases 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24161—Methods of inactivation or attenuation
- C12N2710/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10144664A DE10144664B4 (de) | 2001-09-11 | 2001-09-11 | Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon |
| PCT/EP2002/010199 WO2003023040A2 (en) | 2001-09-11 | 2002-09-11 | Vaccinia virus mva-e3l-knockout-mutants and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1425404T3 true DK1425404T3 (da) | 2008-10-06 |
Family
ID=7698583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02772289T DK1425404T3 (da) | 2001-09-11 | 2002-09-11 | Vaccinia-MVA-E3L-mutanter og anvendelse deraf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7049145B2 (da) |
| EP (1) | EP1425404B1 (da) |
| JP (1) | JP4406561B2 (da) |
| AT (1) | ATE399210T1 (da) |
| AU (1) | AU2002337083A1 (da) |
| CA (1) | CA2459754C (da) |
| DE (2) | DE10144664B4 (da) |
| DK (1) | DK1425404T3 (da) |
| WO (1) | WO2003023040A2 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| JP4606838B2 (ja) * | 2004-10-20 | 2011-01-05 | 富士フイルム株式会社 | 電子内視鏡装置 |
| CA2670804A1 (en) * | 2006-05-19 | 2007-11-29 | Sanofi Pasteur Inc. | Immunological composition |
| WO2010127115A1 (en) | 2009-04-30 | 2010-11-04 | Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) | Modified immunization vectors |
| WO2012050125A1 (ja) | 2010-10-14 | 2012-04-19 | 味の素株式会社 | モナティンの製造方法 |
| FR2969497B1 (fr) * | 2010-12-27 | 2013-06-28 | Ceva Sante Animale | Composition luminescente comme biomarqueur dans un oeuf aviaire, dispositif et procede correspondants. |
| JP6569209B2 (ja) * | 2014-01-07 | 2019-09-04 | ソニー株式会社 | 電気的測定用カートリッジ、並びに電気的測定装置及び電気的測定方法 |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) * | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| CN109152827B (zh) * | 2016-02-25 | 2023-07-21 | 纪念斯隆凯特琳癌症中心 | 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途 |
| JP7025339B2 (ja) | 2016-02-25 | 2022-02-24 | メモリアル スローン ケタリング キャンサー センター | 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス |
| US10842835B2 (en) | 2016-05-25 | 2020-11-24 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY |
| BR112021004692A2 (pt) | 2018-09-15 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | poxvírus recombinantes para imunoterapia de câncer |
| WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| EP3928789A1 (en) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
| WO2022269003A1 (en) | 2021-06-23 | 2022-12-29 | Consejo Superior De Investigaciones Cientificas | MVA-BASED VACCINE EXPRESSING A PREFUSION-STABILIZED SARS-CoV-2 S PROTEIN |
| EP4108257A1 (en) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein |
| EP4316514A1 (en) | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US5990091A (en) * | 1997-03-12 | 1999-11-23 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6287570B1 (en) * | 1998-11-23 | 2001-09-11 | Patricia L. Foley | Vaccine against swine influenza virus |
| WO2000073487A1 (en) * | 1999-05-27 | 2000-12-07 | Arizona Board Of Regents | Novel viral vectors having enhanced effectiveness with dramatically reduced virulence |
| KR101163816B1 (ko) | 2005-09-22 | 2012-07-09 | 도쿄엘렉트론가부시키가이샤 | 플라즈마 처리 방법 및 장치 |
-
2001
- 2001-09-11 DE DE10144664A patent/DE10144664B4/de not_active Expired - Fee Related
-
2002
- 2002-09-11 EP EP02772289A patent/EP1425404B1/en not_active Expired - Lifetime
- 2002-09-11 WO PCT/EP2002/010199 patent/WO2003023040A2/en not_active Ceased
- 2002-09-11 DK DK02772289T patent/DK1425404T3/da active
- 2002-09-11 AT AT02772289T patent/ATE399210T1/de active
- 2002-09-11 US US10/488,987 patent/US7049145B2/en not_active Expired - Fee Related
- 2002-09-11 DE DE60227268T patent/DE60227268D1/de not_active Expired - Lifetime
- 2002-09-11 AU AU2002337083A patent/AU2002337083A1/en not_active Abandoned
- 2002-09-11 CA CA2459754A patent/CA2459754C/en not_active Expired - Fee Related
- 2002-09-11 JP JP2003527104A patent/JP4406561B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050028226A1 (en) | 2005-02-03 |
| CA2459754C (en) | 2011-05-10 |
| CA2459754A1 (en) | 2003-03-20 |
| WO2003023040A2 (en) | 2003-03-20 |
| DE10144664B4 (de) | 2005-06-09 |
| EP1425404A2 (en) | 2004-06-09 |
| JP2005502360A (ja) | 2005-01-27 |
| AU2002337083A1 (en) | 2003-03-24 |
| DE10144664A1 (de) | 2003-03-27 |
| DE60227268D1 (de) | 2008-08-07 |
| JP4406561B2 (ja) | 2010-01-27 |
| EP1425404B1 (en) | 2008-06-25 |
| US7049145B2 (en) | 2006-05-23 |
| ATE399210T1 (de) | 2008-07-15 |
| WO2003023040A3 (en) | 2003-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| NO20056074L (no) | Hoy titer rekombinante influensavira til vaksiner og genterapi | |
| HUP9802217A2 (hu) | Rekombináns MVA-vírus és alkalmazása | |
| CY1105232T1 (el) | Κυτταρικες σειρες συμπληρωματικοτητας | |
| SI1554301T1 (sl) | VAKCINA ZA DENGO, KI VSEBUJE SKUPNO DELECIJO 30 NUKLEOTIDOV V 3ĹľUTR TIPOV 1 IN 2 DENGE | |
| DK1185615T3 (da) | Rekombinante influenzavirus til vacciner og genterapi | |
| ATE508635T1 (de) | Virusvektoren und ihre verwendung bei therapeutischen methoden | |
| UA85536C2 (en) | Viral antigens | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| UA82998C2 (ru) | Экспрессия генов в модифицированном вирусе коровьей оспы ankara с использованием коровьего поксвирусного промотора аті | |
| KR100469936B1 (ko) | 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물 | |
| UA90098C2 (en) | Promoter of vaccinia virus | |
| CY1106570T1 (el) | Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων | |
| IL164179A0 (en) | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter | |
| DK0831899T3 (da) | Rekombinant koppevirus-calicivirus-præparater og anvendelser | |
| NZ603854A (en) | West nile virus vaccine | |
| DE602004015418D1 (de) | Rekombinantes mva und verfahren zur erzeugung davon | |
| DE60040219D1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
| DE60330795D1 (de) | Impfstoff gegen west nile virus | |
| PH12020551944A1 (en) | Reverse peptide vaccine | |
| ATE455854T1 (de) | Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria | |
| PT1383796E (pt) | Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações | |
| WO2024259078A3 (en) | Anti-tick vaccines and methods of use thereof | |
| SE0002498D0 (sv) | Papillomavirus vaccine | |
| BR0318026A (pt) | Antìgenos recombinantes do vìrus da hepatite a, e, uso dos antìgenos |